---
document_datetime: 2025-12-09 23:29:02
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/medicines/human/EPAR/oczyesa.html
document_name: oczyesa.html
version: success
processing_time: 0.2461325
conversion_datetime: 2025-12-24 16:10:54.179522
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
# Oczyesa

[RSS](/en/individual-human-medicine.xml/258591)

##### Authorised

This medicine is authorised for use in the European Union

octreotide Medicine Human Authorised

Page contents

## Page contents

- [Overview](#overview)
- [Product information](#product-info)
- [Product details](#product-details)
- [Authorisation details](#authorisation-details)
- [Assessment history](#assessment-history)
- [News on Oczyesa](#news-on)
- [More information](#more-information-77705)

- Application under evaluation
- CHMP opinion
- European Commission decision

## Overview

Oczyesa is a medicine used for the maintenance (long-term) treatment of acromegaly, a condition where a pituitary adenoma (a non-cancerous tumour in a small gland located at the base of the brain) produces too much growth hormone causing high levels of insulin-like growth factor-1 (IGF-1). This leads to excessive growth of tissues and bones and can also cause diabetes, hypertension (high blood pressure) and cardiovascular disease (conditions affecting the heart and blood circulation).

Oczyesa is used in adults who have previously responded to and tolerated treatment with other somatostatin analogues (man-made (synthetic) versions of the hormone somatostatin).

Oczyesa contains the active substance octreotide and is a 'hybrid medicine'. This means that it is similar to a reference medicine containing the same active substance, but there are certain differences between the two. The reference medicine for Oczyesa is Sandostatin, which is available as a solution for injection at lower strengths than Oczyesa and is also authorised for the treatment of acromegaly.

Expand section

Collapse section

## How is Oczyesa used?

Oczyesa can only be obtained with a prescription.

It is available as a prolonged-release solution for injection in pre-filled pens. Prolonged release means that the active substance is released slowly over a few weeks after being injected. Oczyesa is given once every 4 weeks as an injection under the skin in the belly, thigh or buttock.

Patients switching to treatment with Oczyesa from other somatostatin analogues containing octreotide or lanreotide should take their first dose of Oczyesa at the end of the daily or monthly dosing interval of the previous treatment.

After training, patients may inject Oczyesa themselves if the doctor considers it appropriate.

For more information about using Oczyesa, see the package leaflet or contact your doctor or pharmacist.

## How does Oczyesa work?

The active substance in Oczyesa, octreotide, is a synthetic version of the hormone somatostatin which blocks the release of growth hormone in the pituitary gland. When the medicine attaches to somatostatin receptors (targets), it lowers the levels of growth hormone and as a result also lowers the levels of IGF-1. This is expected to improve disease symptoms, including those related to diabetes and cardiovascular disease.

## What benefits of Oczyesa have been shown in studies?

A main study involved 72 adults with acromegaly who were already being treated with another long-acting somatostatin analogue and were responding to treatment. The study compared Oczyesa with placebo (a dummy treatment). The main measure of effectiveness was the proportion of patients who still had normal levels of IGF-1 between 22 and 24 weeks of treatment. Normal levels of IGF-1 are an established measure for good disease control.

The results showed that around 72% (35 out of 48) of patients receiving Oczyesa had normal levels of IGF-1, compared with 38% (9 out of 24) of those given placebo.

## What are the risks associated with Oczyesa?

For the full list of side effects and restrictions with Oczyesa, see the package leaflet.

The most common side effects with medicines containing octreotide (which may affect up to 1 in 10 people) include abdominal (belly) pain, constipation, flatulence (gas), nausea (feeling sick) and diarrhoea, headache, cholelithiasis (gallstones; hardened pieces of bile that form in the gallbladder), hyperglycaemia (high levels of blood sugar), and reactions at the injection site.

## Why is Oczyesa authorised in the EU?

The European Medicines Agency considered that Oczyesa was effective at maintaining disease control, as assessed by normal IGF-1 levels, in patients with acromegaly. In addition, the medicine is available as pre-filled pens which patients can use themselves after training and can be stored at room temperature. The safety profile of Oczyesa was considered acceptable and comparable to the known safety profile of other somatostatin analogues.

Therefore, the Agency decided that the benefits of Oczyesa are greater than its risks and it can be authorised for use in the EU.

## What measures are being taken to ensure the safe and effective use of Oczyesa?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Oczyesa have been included in the summary of product characteristics and the package leaflet.

As for all medicines, data on the use of Oczyesa are continuously monitored. Suspected side effects reported with Oczyesa are carefully evaluated and any necessary action taken to protect patients.

## Other information about Oczyesa

Oczyesa received a marketing authorisation valid throughout the EU on 30 June 2025.

Oczyesa : EPAR - Medicine overview

Reference Number: EMA/154371/2025

English (EN) (159.99 KB - PDF)

**First published:** 04/07/2025

[View](/en/documents/overview/oczyesa-epar-medicine-overview_en.pdf)

[Other languages (22)](#file-language-dropdown-820)

български (BG) (143.82 KB - PDF)

**First published:**

04/07/2025

[View](/bg/documents/overview/oczyesa-epar-medicine-overview_bg.pdf)

español (ES) (121.74 KB - PDF)

**First published:**

04/07/2025

[View](/es/documents/overview/oczyesa-epar-medicine-overview_es.pdf)

čeština (CS) (145.14 KB - PDF)

**First published:**

04/07/2025

[View](/cs/documents/overview/oczyesa-epar-medicine-overview_cs.pdf)

dansk (DA) (120.29 KB - PDF)

**First published:**

04/07/2025

[View](/da/documents/overview/oczyesa-epar-medicine-overview_da.pdf)

Deutsch (DE) (124.04 KB - PDF)

**First published:**

04/07/2025

[View](/de/documents/overview/oczyesa-epar-medicine-overview_de.pdf)

eesti keel (ET) (118.03 KB - PDF)

**First published:**

04/07/2025

[View](/et/documents/overview/oczyesa-epar-medicine-overview_et.pdf)

ελληνικά (EL) (144.7 KB - PDF)

**First published:**

04/07/2025

[View](/el/documents/overview/oczyesa-epar-medicine-overview_el.pdf)

français (FR) (123.07 KB - PDF)

**First published:**

04/07/2025

[View](/fr/documents/overview/oczyesa-epar-medicine-overview_fr.pdf)

hrvatski (HR) (142.63 KB - PDF)

**First published:**

04/07/2025

[View](/hr/documents/overview/oczyesa-epar-medicine-overview_hr.pdf)

italiano (IT) (120.19 KB - PDF)

**First published:**

04/07/2025

[View](/it/documents/overview/oczyesa-epar-medicine-overview_it.pdf)

latviešu valoda (LV) (151.33 KB - PDF)

**First published:**

04/07/2025

[View](/lv/documents/overview/oczyesa-epar-medicine-overview_lv.pdf)

lietuvių kalba (LT) (144.2 KB - PDF)

**First published:**

04/07/2025

[View](/lt/documents/overview/oczyesa-epar-medicine-overview_lt.pdf)

magyar (HU) (141.86 KB - PDF)

**First published:**

04/07/2025

[View](/hu/documents/overview/oczyesa-epar-medicine-overview_hu.pdf)

Malti (MT) (146.45 KB - PDF)

**First published:**

04/07/2025

[View](/mt/documents/overview/oczyesa-epar-medicine-overview_mt.pdf)

Nederlands (NL) (121.21 KB - PDF)

**First published:**

04/07/2025

[View](/nl/documents/overview/oczyesa-epar-medicine-overview_nl.pdf)

polski (PL) (146.47 KB - PDF)

**First published:**

04/07/2025

[View](/pl/documents/overview/oczyesa-epar-medicine-overview_pl.pdf)

português (PT) (122.36 KB - PDF)

**First published:**

04/07/2025

[View](/pt/documents/overview/oczyesa-epar-medicine-overview_pt.pdf)

română (RO) (141.47 KB - PDF)

**First published:**

04/07/2025

[View](/ro/documents/overview/oczyesa-epar-medicine-overview_ro.pdf)

slovenčina (SK) (143.74 KB - PDF)

**First published:**

04/07/2025

[View](/sk/documents/overview/oczyesa-epar-medicine-overview_sk.pdf)

slovenščina (SL) (169.94 KB - PDF)

**First published:**

04/07/2025

[View](/sl/documents/overview/oczyesa-epar-medicine-overview_sl.pdf)

Suomi (FI) (118.43 KB - PDF)

**First published:**

04/07/2025

[View](/fi/documents/overview/oczyesa-epar-medicine-overview_fi.pdf)

svenska (SV) (119.36 KB - PDF)

**First published:**

04/07/2025

[View](/sv/documents/overview/oczyesa-epar-medicine-overview_sv.pdf)

Oczyesa : EPAR - Risk management plan summary

English (EN) (259.91 KB - PDF)

**First published:** 22/08/2025

[View](/en/documents/rmp-summary/oczyesa-epar-risk-management-plan-summary_en.pdf)

## Product information

Oczyesa : EPAR - Product information

English (EN) (1.05 MB - PDF)

**First published:** 04/07/2025

**Last updated:** 03/12/2025

[View](/en/documents/product-information/oczyesa-epar-product-information_en.pdf)

[Other languages (24)](#file-language-dropdown-553)

български (BG) (1.16 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/bg/documents/product-information/oczyesa-epar-product-information_bg.pdf)

español (ES) (1.05 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/es/documents/product-information/oczyesa-epar-product-information_es.pdf)

čeština (CS) (1.13 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/cs/documents/product-information/oczyesa-epar-product-information_cs.pdf)

dansk (DA) (1.04 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/da/documents/product-information/oczyesa-epar-product-information_da.pdf)

Deutsch (DE) (1.05 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/de/documents/product-information/oczyesa-epar-product-information_de.pdf)

eesti keel (ET) (1.03 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/et/documents/product-information/oczyesa-epar-product-information_et.pdf)

ελληνικά (EL) (1.16 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/el/documents/product-information/oczyesa-epar-product-information_el.pdf)

français (FR) (1.11 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/fr/documents/product-information/oczyesa-epar-product-information_fr.pdf)

hrvatski (HR) (1.11 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/hr/documents/product-information/oczyesa-epar-product-information_hr.pdf)

íslenska (IS) (1.04 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/is/documents/product-information/oczyesa-epar-product-information_is.pdf)

italiano (IT) (1.06 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/it/documents/product-information/oczyesa-epar-product-information_it.pdf)

latviešu valoda (LV) (1.13 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/lv/documents/product-information/oczyesa-epar-product-information_lv.pdf)

lietuvių kalba (LT) (1.14 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/lt/documents/product-information/oczyesa-epar-product-information_lt.pdf)

magyar (HU) (1.12 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/hu/documents/product-information/oczyesa-epar-product-information_hu.pdf)

Malti (MT) (1.18 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/mt/documents/product-information/oczyesa-epar-product-information_mt.pdf)

Nederlands (NL) (1.04 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/nl/documents/product-information/oczyesa-epar-product-information_nl.pdf)

norsk (NO) (1.05 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/no/documents/product-information/oczyesa-epar-product-information_no.pdf)

polski (PL) (878.39 KB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/pl/documents/product-information/oczyesa-epar-product-information_pl.pdf)

português (PT) (1.06 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/pt/documents/product-information/oczyesa-epar-product-information_pt.pdf)

română (RO) (1.14 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/ro/documents/product-information/oczyesa-epar-product-information_ro.pdf)

slovenčina (SK) (1.15 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/sk/documents/product-information/oczyesa-epar-product-information_sk.pdf)

slovenščina (SL) (1.12 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/sl/documents/product-information/oczyesa-epar-product-information_sl.pdf)

Suomi (FI) (1.03 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/fi/documents/product-information/oczyesa-epar-product-information_fi.pdf)

svenska (SV) (1.03 MB - PDF)

**First published:**

04/07/2025

**Last updated:**

03/12/2025

[View](/sv/documents/product-information/oczyesa-epar-product-information_sv.pdf)

**Latest procedure affecting product information:** VR/0000313339 02/12/2025

icon globe

<!-- image -->

This medicine's product information is available in all **official EU languages** . Select 'available languages' to access the language you need.

Product information documents contain:

- summary of product characteristics (annex I);
- manufacturing authorisation holder responsible for batch release (annex IIA);
- conditions of the marketing authorisation (annex IIB);
- labelling (annex IIIA);
- package leaflet (annex IIIB).

## Product details

Name of medicine Oczyesa Active substance octreotide hydrochloride International non-proprietary name (INN) or common name octreotide Therapeutic area (MeSH) Acromegaly Anatomical therapeutic chemical (ATC) code H01CB02

### Pharmacotherapeutic group

Pituitary and hypothalamic hormones and analogues

### Therapeutic indication

Oczyesa is indicated for maintenance treatment in adult patients with acromegaly who have responded to and tolerated treatment with somatostatin analogues.

## Authorisation details

EMA product number EMEA/H/C/006322 Marketing authorisation holder

Camurus AB

Rydbergs Torg 4 224 84 Lund Sweden

Opinion adopted 25/04/2025 Marketing authorisation issued 30/06/2025 Revision 1

## Assessment history

Expand section

Collapse section

## Changes since initial authorisation of medicine

Oczyesa : EPAR - Procedural steps taken and scientific information after authorisation

English (EN) (141.88 KB - PDF)

**First published:** 03/12/2025

[View](/en/documents/procedural-steps-after/oczyesa-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf)

## Initial marketing authorisation documents

Oczyesa : Orphan designation withdrawal assessment report (initial-authorisation)

Adopted

Reference Number: EMADOC-1700519818-2149851

English (EN) (1.96 MB - PDF)

**First published:** 04/07/2025

[View](/en/documents/orphan-maintenance-report/oczyesa-orphan-designation-withdrawal-assessment-report-initial-authorisation_en.pdf)

Oczyesa : EPAR - Public assessment report

Adopted

Reference Number: EMA/164079/2025

English (EN) (3.41 MB - PDF)

**First published:** 04/07/2025

[View](/en/documents/assessment-report/oczyesa-epar-public-assessment-report_en.pdf)

CHMP summary of positive opinion for Oczyesa

Adopted

Reference Number: EMA/CHMP/132414/2025

English (EN) (144.71 KB - PDF)

**First published:** 25/04/2025

[View](/en/documents/smop-initial/chmp-summary-positive-opinion-oczyesa_en.pdf)

#### News on Oczyesa

[Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 April 2025](/en/news/meeting-highlights-committee-medicinal-products-human-use-chmp-22-25-april-2025) 25/04/2025

#### More information

Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2025 on request of the Sponsor.

**This page was last updated on** 03/12/2025

## Share this page

[Back to top](#main-content)